论文部分内容阅读
目的 探讨p2 1WAF1/CIP1蛋白在乳腺癌中表达的临床意义。方法 运用免疫组化SP法半定量检测p2 1蛋白在癌旁正常乳腺组织、乳腺癌组织中的表达。结果 p2 1蛋白表达位于细胞核 ,呈棕黄色。在 2 0例癌旁正常乳腺组织中 ,无p2 1蛋白表达。在 69例乳腺癌组织中有 3 0例p2 1蛋白阳性表达。在乳腺癌组织中 ,随组织学分级升高 ,p2 1阳性率下降 (P <0 0 5 ) ,随临床分期升高 ,p2 1阳性率下降 (P <0 0 5 )。有淋巴结转移组p2 1阳性率低于无淋巴结转移组 (P <0 0 5 )。p2 1蛋白阳性表达者术后 5年无瘤生存率高于p2 1蛋白阴性者术后 5年无瘤生存率 (P <0 0 5 )。结论 p2 1蛋白可用来评估乳腺癌细胞分化情况及转移潜能 ,可判断乳腺癌患者预后。
Objective To investigate the clinical significance of p2 1WAF1 / CIP1 protein in breast cancer. Methods The expression of p21 protein in normal breast tissues and breast cancer tissues was detected by immunohistochemical SP method. Results p2 1 protein was located in the nucleus, showing a yellowish brown color. In 20 cases of adjacent normal breast tissue, no p2 1 protein expression. In 69 cases of breast cancer, 30 cases of p21 protein positive expression. In breast cancer, the positive rate of p21 was decreased with the increase of histological grade (P <0.05). The positive rate of p21 was decreased with the increase of clinical stage (P <0.05). The positive rate of p21 in patients with lymph node metastasis was lower than that without lymph node metastasis (P <0.05). The 5-year disease-free survival rate of patients with p21 protein positive expression was higher than that of p2 1 protein negative patients after 5 years (P <0.05). Conclusion p2 1 protein can be used to evaluate the differentiation and metastatic potential of breast cancer cells and to determine the prognosis of breast cancer patients.